This immunotherapeutic chimera resulted in efficient NMD-targeted inhibition in CD40-expressing B-cell lymphomas while providing optimal conditions for cancer immunotherapy; activation of antigen-presenting cells, enhancement of tumor antigenicity, and bone-marrow aplasia recovery [68]. This evidence concerns the gene CD40 and B-cell non-Hodgkin lymphoma.